Isnt that article an old one? Things have changed since then. You really didnt answer my question and i would appreciate it if anyone could respond! Thanks in advance.
NPC BLOG Nutra Pharma Bites Back – A Response to the Dow Jones Newswires Posted on Oct 12th, 2009 by Rik J. Deitsch
On Friday, an article came out from Dow Jones Newswires that discussed Nutra Pharma and our launch of Cobroxin. While the article was factually correct and well written, the author left out critical pieces of information that failed to tell the entire story about Nutra Pharma.
While at first glance, our balance sheet looks soft. We have several million dollars in liabilities and our latest quarterly from the SEC reported little cash in-hand. But at closer inspection, one would realize that over the years, I have funded the company over $3 million out of my own pocket to continue our drug development work on Multiple Sclerosis (MS), pain, HIV/AIDS, and Adrenomyeloneuropathy (AMN). Because of my strong belief in our pipeline, I chose to provide this financing as a loan to the company, instead of diluting shareholders. This financing now makes up the majority of the $3.1 million liability.
Today, the company is as strong as ever. Not only are we in the process of launching our first product in the United States, but we are also much stronger financially with over $2.5 million in cash that we plan to use to finance the manufacturing of Cobroxin and additional clinical studies for our other drug indications.
As we move forward with the launch of Cobroxin this week, it is important that our customers and shareholders understand the history of the product and its clinical profile. The active pharmaceutical ingredient (API) in our branded pain reliever, Cobroxin, is Asian cobra venom. We have been studying cobra venom for the past 10 years at our drug discovery subsidiary, ReceptoPharm under the supervision of Dr. Paul Reid. Dr. Reid acts as the CEO of ReceptoPharm and is one of the world’s foremost experts on cobra venom. He first started studying it when he was at the United States Medical Research Institute for Infectious Diseases (USMRIID) at Fort Detrick, Maryland, under a grant from the National Research Council in Washington, D.C.
Cobra venom dates further back than Dr. Reid’s original work in the early 1990s. It has been used in the U.S. for over 75 years and has a well understood clinical application. There are 46 human clinical trials dating back to the 1930s and 20 pre-clinical studies using cobra venom to treat pain, including some of the most recent work being completed by Dr. Paul Reid from ReceptoPharm and Dr. Zheng-Hong Qin, who divides his time between Harvard University/Massachusetts General Hospital in Boston and Soochow University in Suzhou, China.
Unfortunately, a point of confusion in the recent article was that it stated that Nutra Pharma is in the process of completing human clinical trials in an effort to gather as much information as possible about Cobroxin. In fact, we are planning to conduct an additional trial for Nyloxin Rx, our prescription pain reliever, to compare its efficacy to other prescription pain medicines. We believe that the results of this comparison study could provide us with excellent evidence showing that Nyloxin Rx should be the preferred method of treatment for severe (Stage 3) chronic pain. Additional details will be released as we move into the launch of Nyloxin Rx.
While we would like to claim Cobroxin as a new product, it is not. Cobra venom has been used as a therapeutic agent in China for thousands of years for a variety of different purposes. Additionally, here in the United States, cobra venom is a U.S. monographed drug under the Homeopathic Pharmacopoeia (HPUS) and was used as a pain killer by the United States government during World War II.
As cortisone became popular and other pain killers became accessible in the United States, people stopped using cobra venom primarily because it lacked standardization. 50 years ago, the technology to measure the amount or type of peptides and whether there was bacterial or fungal contamination did not exist. Additionally, there were no tools available to properly clean, sterilize and standardize the solution, so patients would end up with ineffective and bad batches. Today, however, with our understanding of cobra venom peptides and the technology that we have available, we can tell you exactly what is in every batch and verify that it is sterile, clean and that it is going to be effective. Our understanding of this product and the technology we have available to us is why I believe cobra venom will once again become a staple for treating pain.
A critical part of the launch of Cobroxin is our licensing partnership with XenaCare Holdings. What drew us to XenaCare was not only the company’s commitment to a several million dollar roll-out, but also its relationship with a broker network that is considered among the leaders in the industry with a history for launching successful products, several of which now have over a billion dollars in sales. While we are confident that XenaCare is fully-capable of completing a successful launch of Cobroxin by utilizing its available financial and human capital, our agreement, as would any out-licensing agreement, requires XenaCare to meet certain minimum performance requirements.
If you would like to learn more about the science behind Cobroxin, I invite you to click here to listen to a webinar I hosted last month discussing the product. I believe this will help clarify the science behind the Cobroxin and why cobra venom is effective for treating Stage 2 chronic pain.
In summary, I would like to reiterate how excited we are about Nutra Pharma and the blockbuster potential of our drug discovery platform. As we move forward on all of our initiatives and transition into a revenue producing company, I would like to invite you to reach out directly to our investor relations department at (877) 895-5647 or by email at ir@nutrapharma.com with any questions you have about the Company. We pride ourselves on remaining as transparent as possible to our shareholders and will continue with this effort as we complete the launch of Cobroxin and the continued develop of our drug pipeline.
SEC Disclaimer This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The article, "Nutra Pharma Bites Back – A Response to the Dow Jones Newswires", should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
3 Comments »
Cobroxin - Our Over-the-Counter (OTC) Treatment for Chronic Pain Posted on Sep 8th, 2009 by Rik J. Deitsch
Just over 2 weeks ago, we announced the launch of Cobroxin, a pain reliever developed by our subsidiary, ReceptoPharm. Since making that announcement, we have been inundated with calls and emails asking us about Cobroxin and our launch strategy. To help answer these questions, I have put together the following list of some of the most popular questions people have been asking us:
What is Cobroxin?
Cobroxin is the first over-the-counter pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. It is primarily intended to help with lower back pain, migraines, neck aches, shoulder pain, cramps, neuralgia, joint pain and pain associated with repetitive stress and arthritis.
How is Cobroxin different than Tylenol and prescription pain medicine?
Cobroxin is a new type of pain reliever that does not rely on acetaminophen or opiates for its pain relieving effects. Instead, Cobroxin uses a novel mechanism of action that Nutra Pharma’s drug discovery subsidiary, ReceptoPharm, has been studying for the past 10 years - a peptide from cobra venom.
Is it odd to use venom in medicine?
While at first glance, it might seem odd to use cobra venom for pain relief, however, it is not uncommon to see venoms used in medicine. In fact, there are several drugs that use venoms, including a Type 2 Diabetes drug, Byetta, formulated from the poisonous saliva of the Gila monster, and a heart drug, Aggrastat, that is based on proteins from the African saw-scaled viper.
Have pharmaceutical companies approached you about Cobroxin?
Over the past 12 months, we have been approached by several large pharmaceutical companies based here in the United States and abroad. Most of these firms are primarily interested in our research on Multiple Sclerosis (MS) and Adrenomyeloneuropathy (AMN), however, this interest may shift towards pain as we move forward with our Cobroxin launch.
Are there any patents protecting Cobroxin?
Nutra Pharma, ReceptoPharm and Designer Diagnostics own patents protecting their various products. For a more specific answer about Cobroxin, I would refer you to a recent press release from Nutra Pharma entitled “Nutra Pharma Subsidiary, ReceptoPharm, Files Patent Application for the Oral Delivery of Cobra Venom for the Treatment of Pain“.
When will Cobroxin be available and where will it be sold?
We plan to introduce Cobroxin through retailers across the country and are continuing to work diligently to place Cobroxin on retail shelves as quickly as possible. We expect Cobroxin will be available at several leading retailers as early as October.
What type of response have you received from retailers?
The response from retailers has been overwhelmingly positive. For instance, in August, we attended the Efficient Collaborative Retail Marketing conference in Miami, Florida. Each year, this show draws the largest and most well respected retailers from across the country. At this show, we won “Best New Product”, an award selected by the conference attendees, which included many of the major national retailers. Receiving this award was confirmation that retailers believe in Cobroxin.
How much will Cobroxin cost?
Cobroxin will have a suggested retail price of $18.99 for the oral spray and $19.95 for the topical gel, making it one of the most affordable analgesics for moderate to severe chronic pain.
Are you distributing Cobroxin or have you licensed the product to another company?
We recently finalized a key licensing agreement with XenaCare Holdings, which grants them the exclusive rights to distribute Cobroxin in the United States. XenaCare Holdings has continued to commit significant time, financial resources and industry expertise towards the launch of Cobroxin.
Is Cobroxin FDA Approved?
Cobroxin does not require FDA approval because it falls within the regulatory environment of the United States Homeopathic Pharmacopoeia. Unlike most homeopathic medicines, however, the efficacy and safety of Cobroxin is supported by significant clinical evidence including over 46 human clinical studies documenting the use of cobra venom as a pain reliever. Click here for a list of these clinical studies.
Has anyone been using this product already, and if so, how successfully?
We had a limited supply of Cobroxin manufactured, which we then distributed to friends and family. So far, we have received positive reports of Cobroxin helping with knee pain, back pain, shoulder pain and general chronic pain, even for those who have been unsuccessful with other pain medication. This gives us added confidence as we move forward with the national launch.
Can you elaborate on the future products that were mentioned in the press release from August 24th?
For those who have not read that press release, it made a brief comment that we are continuing to finalize formulations for a prescription-only analgesic and a pain reliever for the veterinary market. We have always planned to have a prescription-only analgesic and initially considered launching that before the over-the-counter (OTC) version. Because we are launching Cobroxin as an OTC first, it is likely that a prescription-only analgesic will be our next product coming to market.
Additionally, we have always had an interest in animal health. Originally, our focus was on antiviral medicines, such as the treatment we are developing for Feline Leukemia. Nonetheless, we believe that the opportunity exists for an affordable pain reliever for this market and we plan to pursue that in the near-term.
How can I learn more about Cobroxin?
If you have an interest in learning more about Cobroxin, be sure to visit the product website at http://www.Cobroxin.com. Additionally, I invite you to click here to register for an upcoming online presentation I am giving about the science behind Cobroxin.
With all of the news and excitement surrounding Cobroxin, it is important for us to stress that we are committed to continuing our research on Adrenomyeloneuropathy (AMN), Multiple Sclerosis (MS), HIV, and Hepatitis C. This is important research and, while we are in the midst of our first product launch, our focus on developing treatments for these other indications has not wavered.
In closing, I would like to remind those who have an interest in following Nutra Pharma’s progress to sign up for our E-Alerts. This will provide you with the most recent news, announcements and blog postings from our company.
SEC Disclaimer This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The article, "Cobroxin - Our Over-the-Counter (OTC) Treatment for Chronic Pain", should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Remond's article is old and disputed already if you cared to do DD on this. We've also shown that she has been busted as a tout and a basher, and refuses to answer calls when she's challenged on this. Look it up.
News 
Market Data 
Discover 
AI
